Anticoagulant therapy for splanchnic vein thrombosis

Nisio, Marcello Di; Valeriani, Emanuele; Riva, Nicoletta; Schulman, Sam; Beyer‐Westendorf, Jan; Ageno, Walter

doi:10.1111/jth.14836

Cited by 79 publications

(81 citation statements)

References 44 publications

(153 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3,4 The occurrence of splanchnic vein thrombosis may cause or worsen portal hypertension and impair liver function, which could negatively affect patients' prognosis. 9,32 In the current study, over half of patients died within 12 months, with no survival difference between those receiving anticoagulant therapy and patients who were left untreated. The risk of death was comparable between patients with splanchnic vein thrombosis and usual site VTE, despite the proportion of patients with metastatic cancer being significantly higher in the latter than in the former group.…”

Section: Discussionmentioning

confidence: 55%

“…Whether anticoagulant therapy improves survival of patients with splanchnic vein thrombosis remains unclear 3,4 . The occurrence of splanchnic vein thrombosis may cause or worsen portal hypertension and impair liver function, which could negatively affect patients’ prognosis 9,32 . In the current study, over half of patients died within 12 months, with no survival difference between those receiving anticoagulant therapy and patients who were left untreated.…”

Section: Discussionmentioning

confidence: 57%

See 1 more Smart Citation

Clinical history of cancer‐associated splanchnic vein thrombosis

Valeriani

Nisio

Riva

et al. 2021

Journal of Thrombosis and Haemostasis

Self Cite

View full text Add to dashboard Cite

Background: Cancer represents a risk factor for splanchnic vein thrombosis (SVT) and usual site venous thromboembolism (VTE). Objectives: To compare characteristics and outcomes of patients with cancerassociated SVT and usual site VTE. Patients/Methods: Patients with solid cancer and SVT were enrolled in an international, prospective registry between May 2008 and January 2012. The comparison cohort included (1:1 ratio) patients with solid cancer and usual site VTE treated at two thrombosis centers who had a minimum of 12 months follow-up at December 2019 or experienced one of the outcomes within 12 months follow-up.

show abstract

Section: Discussionmentioning

confidence: 55%

Section: Discussionmentioning

confidence: 57%

Clinical history of cancer‐associated splanchnic vein thrombosis

Valeriani

Nisio

Riva

et al. 2021

Journal of Thrombosis and Haemostasis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several observational studies have shown that early initiation of anticoagulation is associated with better vessel recanalization, which in particular can reduce the occurrence of portal-hypertension-related complications. 23 24 Thus, anticoagulant therapy in patients with acute splanchnic vein thrombosis should be started early after diagnosis, if there is no active bleeding, 25 to avoid the extension of the clot and promote vessel recanalization. If esophageal varices are present, implementation of adequate prophylaxis such as nonselective β-blockers or endoscopic variceal band ligation is recommended and full anticoagulation should be started after complete endoscopic variceal eradication is obtained, if required.…”

Section: Splanchnic Vein Thrombosismentioning

confidence: 99%

Treatment of Atypical Clots

Ageno

2022

Hamostaseologie

Self Cite

View full text Add to dashboard Cite

The term unusual site thrombosis refers to the occurrence of venous thromboembolism outside of the lower limbs and the pulmonary arteries. Unusual site thrombosis can virtually affect any venous segment, with the most common and/or clinically relevant sites including the upper limbs veins, the retinal veins, the splanchnic veins and the cerebral veins. Clinical features are obviously heterogeneous, while many predisposing factors are common, though with different prevalence among the various disorders. Antithrombotic therapy is prescribed to most patients, but the type, intensity, and duration of treatment vary both within and among patient groups. Increasing evidence is supporting the use of the direct oral anticoagulants in patients with upper limb deep vein thrombosis, cerebral vein thrombosis, and with splanchnic vein thrombosis. This article will review available evidence on the treatment of venous thrombosis occurring in unusual sites.

show abstract

“…For references, see Di Nisio et al 1 Anticoagulant Therapy for Splanchnic Vein Thrombosis: Summary of Suggested Treatment Strategies Venous thromboprophyla xis in the intensive c are unit…”

Section: S Planchnic Vein Thrombosis Walter Ageno MDmentioning

confidence: 99%

“…For references, see Handrkova et al,, 53 Li et al, 54 The acƟvaƟon pepƟde, and in parƟcular the sequence 8 FGGR 12 R, stabilizes the FXIII A 2 dimer [1] Four intersubunit interacƟons located at the dimer interface stabilize the…”

Section: Verena Schroeder Phdmentioning

confidence: 99%

Illustrated State‐of‐the‐Art Capsules of the ISTH 2021 Congress

Krishnaswamy

Ageno

Arabi³

et al. 2021

Research and Practice in Thrombosis and Haemostasis

Self Cite

View full text Add to dashboard Cite

This year's Congress of the International Society of Thrombosis and Haemostasis (ISTH) was hosted virtually from Philadelphia July 17–21, 2021. The conference, now held annually, highlighted cutting‐edge advances in basic, population and clinical sciences of relevance to the Society. Despite being held virtually, the 2021 congress was of the same scope and quality as an annual meeting held in person. An added feature of the program is that talks streamed at the designated times will then be available on‐line for asynchronous viewing. The program included 77 State of the Art (SOA) talks, thematically grouped in 28 sessions, given by internationally recognized leaders in the field. The SOA speakers were invited to prepare brief illustrated reviews of their talks that were peer reviewed and are included in this article. The topics, across the main scientific themes of the congress, include Arterial Thromboembolism, Coagulation and Natural Anticoagulants, COVID‐19 and Coagulation, Diagnostics and Omics, Fibrinogen, Fibrinolysis and Proteolysis, Hemophilia and Rare Bleeding Disorders, Hemostasis in Cancer, Inflammation and Immunity, Pediatrics, Platelet Disorders, von Willebrand Disease and Thrombotic Angiopathies, Platelets and Megakaryocytes, Vascular Biology, Venous Thromboembolism and Women's Health. These illustrated capsules highlight the major scientific advances with potential to impact clinical practice. Readers are invited to take advantage of the excellent educational resource provided by these illustrated capsules. They are also encouraged to use the image in social media to draw attention to the high quality and impact of the science presented at the congress.

show abstract

Anticoagulant therapy for splanchnic vein thrombosis

Cited by 79 publications

References 44 publications

Clinical history of cancer‐associated splanchnic vein thrombosis

Clinical history of cancer‐associated splanchnic vein thrombosis

Treatment of Atypical Clots

Illustrated State‐of‐the‐Art Capsules of the ISTH 2021 Congress

Contact Info

Product

Resources

About